PMID- 22790891
OWN - NLM
STAT- MEDLINE
DCOM- 20130724
LR  - 20191210
IS  - 2185-4610 (Electronic)
IS  - 0016-2590 (Linking)
VI  - 58
IP  - 1
DP  - 2012
TI  - Clinical evaluation of dendritic cells vaccination for advanced cancer patients 
      at Fukushima Medical University.
PG  - 40-8
AB  - Dendritic cells (DCs) are powerful antigen-presenting cells (APCs) that have 
      attracted attention in recent years from the viewpoint of DC vaccine therapy 
      against cancer. However, the existence of a strongly immunosuppressed state in 
      cancer-bearing individuals inhibits DC maturation, which is one of the problems 
      facing anti-cancer DC vaccine therapy. Isolated DCs loaded with tumor antigen ex 
      vivo and administered as a cellular vaccine have been found to induce protective 
      and therapeutic anti-tumor immunity in experimental animals. In clinical trials 
      of DC vaccination for cancer patients, induction of anti-tumor immune responses 
      and tumor regression has been observed. In this study, eighty-one advanced cancer 
      patients unsuccessfully treated by established treatment in individual cases were 
      selected between January 2002 and May 2007 at Fukushima Medical University. The 
      usefulness of DC therapy was investigated by intradermal injection of peptide 
      pulsed DCs for an overall objective response rate of 28.0%. Furthermore, direct 
      injection of immature DCs into tumor extracted an overall objective response rate 
      of 35.7%, and especially 40.0% for advanced pancreatic cancer by using endoscopic 
      ultrasound-guided fine-needle injection technique as a novel approach. These 
      results indicate that DC-based vaccination could be a promising treatment 
      modality for various cancers, however multiple hurdles must be cleared before the 
      development of an affordable DC-based vaccination can be used worldwide.
FAU - Nakamura, Izumi
AU  - Nakamura I
AD  - Department of Organ Regulatory Surgery. izumin@fmu.ac.jp
FAU - Kanazawa, Masashi
AU  - Kanazawa M
FAU - Sato, Yu
AU  - Sato Y
FAU - Irisawa, Atsushi
AU  - Irisawa A
FAU - Takagi, Tadayuki
AU  - Takagi T
FAU - Ogata, Takashi
AU  - Ogata T
FAU - Kashimura, Shogo
AU  - Kashimura S
FAU - Kenjo, Akira
AU  - Kenjo A
FAU - Suzuki, Hiroyuki
AU  - Suzuki H
FAU - Shibata, Masahiko
AU  - Shibata M
FAU - Shimura, Tatsuo
AU  - Shimura T
FAU - Ohira, Hiromasa
AU  - Ohira H
FAU - Goto, Mitsukazu
AU  - Goto M
FAU - Takenoshita, Seiichi
AU  - Takenoshita S
FAU - Ohto, Hitoshi
AU  - Ohto H
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - Japan
TA  - Fukushima J Med Sci
JT  - Fukushima journal of medical science
JID - 0374626
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, Neoplasm/immunology
MH  - Cancer Vaccines/administration & dosage/immunology/*therapeutic use
MH  - Dendritic Cells/immunology/*transplantation
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/immunology/*prevention & control
MH  - Vaccination
EDAT- 2012/07/14 06:00
MHDA- 2013/07/25 06:00
CRDT- 2012/07/14 06:00
PHST- 2012/07/14 06:00 [entrez]
PHST- 2012/07/14 06:00 [pubmed]
PHST- 2013/07/25 06:00 [medline]
AID - DN/JST.JSTAGE/fms/58.40 [pii]
AID - 10.5387/fms.58.40 [doi]
PST - ppublish
SO  - Fukushima J Med Sci. 2012;58(1):40-8. doi: 10.5387/fms.58.40.